SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-066746
Filing Date
2024-05-30
Accepted
2024-05-30 17:04:09
Documents
11
Period of Report
2024-05-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K omga-20240528.htm   iXBRL 8-K 47967
  Complete submission text file 0000950170-24-066746.txt   170650

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT omga-20240528.xsd EX-101.SCH 29309
14 EXTRACTED XBRL INSTANCE DOCUMENT omga-20240528_htm.xml XML 4885
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40657 | Film No.: 241006382
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)